|
Cost-effectiveness of interventions for chronic obstructive pulmonary disease (COPD) using an Ontario policy model |
Chandra K, Blackhouse G, McCurdy BR, Bornstein M, Campbell K, Costa V, Franek J, Kaulback K, Levin L, Sehatzadeh S, Sikich N, Thabane M, Goeree R |
|
|
Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Chandra K, Blackhouse G, McCurdy BR, Bornstein M, Campbell K, Costa V, Franek J, Kaulback K, Levin L, Sehatzadeh S, Sikich N, Thabane M, Goeree R. Cost-effectiveness of interventions for chronic obstructive pulmonary disease (COPD) using an Ontario policy model. Toronto: Medical Advisory Secretariat (MAS). Volume 12(12). 2012 Authors' objectives The objective of this study was to evaluate the cost-effectiveness and budget impact of the following interventions in moderate to very severe COPD, investigated in the Medical Advisory Secretariat Chronic Obstructive Pulmonary Disease Mega-Analysis Series:
- smoking cessation programs in moderate COPD in an outpatient setting:
– intensive counselling (IC) versus usual care (UC)
– nicotine replacement therapy (NRT) versus UC
– IC + NRT versus placebo
– bupropion versus placebo
- multidisciplinary care (MDC) teams versus UC in moderate to severe COPD in an outpatient setting
- pulmonary rehabilitation (PR) versus UC following acute exacerbations in moderate to severe COPD
- long-term oxygen therapy (LTOT) versus UC in severe hypoxemia in COPD in an outpatient setting
- ventilation:
– noninvasive positive pressure ventilation (NPPV) + usual medical care versus usual medical care in acute respiratory failure due to an acute exacerbation in severe COPD in an inpatient setting
– weaning with NPPV versus weaning with invasive mechanical ventilation in acute respiratory failure due to an acute exacerbation in very severe COPD in an inpatient setting Authors' conclusions Currently, costs for most of these interventions are being absorbed by provider services, the Ontario Drug Benefit Program, the Assistive Devices Program, and the hospital global budget. The most cost-effective intervention for COPD will depend on decision-makers' willingness to pay. Lack of provincial data sets capturing resource utilization for the various interventions poses a challenge for estimating current burden and future expenditures. Indexing Status Subject indexing assigned by CRD MeSH Cost-Benefit Analysis; Ontarios; Pulmonary Disease, Chronic Obstructive Language Published English Country of organisation Canada English summary An English language summary is available. Address for correspondence Medical Advisory Secretariat, Ontario Ministry of Health and Long Term Care, 20 Dundas Street West, 10th Floor, Toronto, ON M5G 2N6 Canada Email: MASinfo.moh@ontario.ca AccessionNumber 32012000635 Date abstract record published 21/09/2012 |
|
|
|